Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
EBITDA before special items falls 1.3 percent to € 4.41 billion
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Subscribe To Our Newsletter & Stay Updated
